Nipocalimab Can Delay, Prevent Anemia, Intrauterine Transfusion
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Aug. 7, 2024 -- For pregnancies at high risk for early-onset severe hemolytic disease of the fetus and newborn (HDFN), intravenous nipocalimab can delay or prevent fetal anemia or intrauterine transfusions, according to a study published online Aug. 7 in the New England Journal of Medicine.
Kenneth J. Moise Jr., M.D., from Dell Medical School at the University of Texas at Austin, and colleagues examined treatment with intravenous nipocalimab (30 or 45 mg/kg body weight per week) administered from 14 to 35 weeks of gestation in participants with pregnancies at high risk for recurrent early-onset severe HDFN.
The researchers found that seven of 13 pregnancies in the study had live birth at 32 weeks of gestation or later without intrauterine transfusions (54 percent). There were no cases of fetal hydrops; in six cases (46 percent), participants did not receive any antenatal or neonatal transfusions. An intrauterine transfusion was received by six fetuses: five at 24 weeks of gestation or later and one before fetal loss at 22 weeks and five days of gestation. Twelve pregnancies had live births, with a median gestational age at delivery of 36 weeks and four days. One of the 12 live-born infants received one exchange transfusion and one simple transfusion, and five received only simple transfusions. Maternal samples and cord blood had treatment-related decreases in the alloantibody titer and immunoglobulin G level.
"These preliminary efficacy results, together with the preliminary safety data and evidence of the anticipated drug mechanisms, support the further evaluation of nipocalimab in severe HDFN," the authors write.
The study was funded by Janssen Research and Development, which is developing nipocalimab.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
Maternal Anemia in Early Pregnancy May Increase Risk for Congenital Heart Disease
WEDNESDAY, April 23, 2025 -- Maternal anemia in early pregnancy is associated with an increased risk for congenital heart disease (CHD) in offspring, according to a study...
Six-Month Mortality Lower With Liberal Transfusion Strategy in Acute MI With Anemia
MONDAY, Jan. 6, 2025 -- For patients with acute myocardial infarction (MI) and anemia, the primary outcome of 30-day mortality or MI does not differ with a restrictive versus...
More Than Half of People With Rheumatoid Arthritis Have Anemia
THURSDAY, Jan. 2, 2025 -- Anemia is prevalent among patients with rheumatoid arthritis (RA), according to a study published online Oct. 26 in Cureus. Jamal Shah, M.B.B.S...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.